Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trial aims to slash COVID-19 deaths and ventilator use

NCT ID NCT04488081

Disease control Sponsor: QuantumLeap Healthcare Collaborative Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests several experimental treatments at once in critically ill COVID-19 patients who need high-flow oxygen or a ventilator. The goal is to quickly find which treatments can reduce deaths and shorten the time patients need breathing support. About 1,500 adults in the hospital are participating.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for participation in this study: A. Male or Female, at least 18 years old B. Admitted to the hospital and placed on high flow oxygen (≥6L by nasal cannula or mask delivery system) or intubated for the treatment of (established or presumed) COVID-19. C. Informed consent provided by the patient, LAR or health care proxy. D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS- CoV-2 infection prior to randomization. Exclusion Criteria: A. Pregnant or breastfeeding women (must be documented by a pregnancy test during hospitalization) B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history. C. Comfort measures only. D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11. E. Resident for more than six months at a skilled nursing facility. F. Estimated mortality greater than 50% over the next six months from underlying chronic conditions. G. Time since requirement for high flow oxygen or ventilation greater than 5 days. H. Anticipated transfer to another hospital which is not a study site within 72 hours. I. Patients with either end-stage kidney disease or acute kidney injury who are on dialysis. J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND. K. On 3 or more vasopressors. L. Pre-existing heart failure with a known left ventricular ejection fraction \<25% or unstable angina pectoris.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult acute respiratory distress syndrome COVID-19 disease respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Corewell Health

    Grand Rapids, Michigan, 49503, United States

  • DHR Health

    Edinburg, Texas, 78539, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Georgetown University

    Washington D.C., District of Columbia, 20007, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Kaiser LAMC

    Los Angeles, California, 90027, United States

  • Kalispell Regional Medical Center

    Kalispell, Montana, 59901, United States

  • Lankenau Medical Center (Mainline Health)

    Wynnewood, Pennsylvania, 19096, United States

  • Logan Health Medical Center

    Kalispell, Montana, 59901, United States

  • Long Beach Memorial Medical Center

    Long Beach, California, 90806, United States

  • Main Line Health - Lankenau Medical Center

    Wynnewood, Pennsylvania, 19096, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Sanford Health

    Souix Falls, South Dakota, 57109, United States

  • Stamford Health

    Stamford, Connecticut, 06904, United States

  • UC Davis Medical Center

    Davis, California, 95817, United States

  • UC Irvine Medical Center

    Irvine, California, 92868, United States

  • University Hospital Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of California San Francisco (UCSF)

    San Francisco, California, 94115, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Florida

    Gainesville, Florida, 32608, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Miami

    Coral Gables, Florida, 33124, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania (U Penn)

    Philadelphia, Pennsylvania, 19104, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • University of Southern California

    Los Angeles, California, 90033, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Virtua Mount Holly Hospital

    Mount Holly, New Jersey, 08060, United States

  • Virtua Voorhees Hospital

    Voorhees Township, New Jersey, 08043, United States

  • WVU Medicine

    Morgantown, West Virginia, 26506, United States

  • Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina, 27157, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.